Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.

Topics Artificial Intelligence

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip? ↗

October 15, 2024

Topics Artificial Intelligence

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

October 08, 2024

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains ↗

October 07, 2024

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Topics Artificial Intelligence

October 02, 2024

From Recursion Pharmaceuticals, Inc.

It largely depends on your investing style.

Is Recursion Pharmaceuticals Stock a Buy? ↗

September 20, 2024

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Looking Into Recursion Pharmaceuticals's Recent Short Interest ↗

September 16, 2024

Via Benzinga

October 30, 2024

Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia

From Recursion Pharmaceuticals

This company stands to benefit from a shifting pharmaceutical industry landscape.

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock ↗

October 26, 2024

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

October 22, 2024

From Recursion Pharmaceuticals, Inc.

The key word here is "could."

Prediction: These 2 Stocks Could Soar in 2025 ↗

October 17, 2024

The Ark Invest portfolio is known for taking aggressive bets.

Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals ↗

September 04, 2024

Via Benzinga

How Is The Market Feeling About Recursion Pharmaceuticals? ↗

August 23, 2024

Via Benzinga

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk ↗

September 29, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual...

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗

September 15, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual...

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗

September 10, 2024

September 07, 2024

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗

Topics Economy

September 05, 2024

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug...

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

Topics Economy

Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher ↗

September 03, 2024

Via Benzinga

September 03, 2024

Via Benzinga

Nasdaq Dips Over 2%; US Construction Spending Falls In July ↗

September 03, 2024

Via Benzinga

Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On? ↗

September 03, 2024

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation...

Via Benzinga

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 03, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment...

From Recursion Pharmaceuticals, Inc.

Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider.

Is Recursion Pharmaceuticals a Warren Buffett Stock? ↗

August 30, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.

Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗

August 27, 2024

Merging with a former rival will bolster its capabilities.

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. ↗

August 18, 2024

We'll know a little more about the biotech's prospects in a year and a half.

Is Recursion Pharmaceuticals Stock a Buy? ↗

August 17, 2024

The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...

AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗

August 14, 2024

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

August 14, 2024

Via FinancialNewsMedia

Topics Artificial Intelligence

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

August 14, 2024

From FN Media Group LLC